1,277 results on '"Park, Jae H"'
Search Results
2. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.
3. Loss of function of phosphatidylserine synthase causes muscle atrophy in Drosophila
4. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
5. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
6. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
7. Low-Temperature Flexible WPU-PDMS Copolymers for Cold-Resistant Coating Applications
8. Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
9. Cooperative CAR targeting to selectively eliminate AML and minimize escape
10. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
11. Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
12. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
13. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
14. A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).
15. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.
16. Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
17. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
18. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
19. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis
20. Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia
21. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
22. Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
23. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
24. CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit
25. Biogenesis of circular RNAsin vitroandin vivofrom theDrosophila Nk2.1/scarecrowgene
26. Quality of Life in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Obecabtagene Autoleucel (obe-cel) in the Pivotal Phase 2 Felix Study
27. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort
28. Site-Specific Response Rates in Large B-Cell Lymphomas Treated with CD19-CART Therapy.
29. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells
30. Phosphatidylserine synthase plays an essential role in glia and affects development, as well as the maintenance of neuronal function
31. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
32. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
33. Visualization of one-dimensional diffusion and spontaneous segregation of hydrogen in single crystals of VO2
34. Managing older adults with Ph-negative ALL: What is new? Recent advances in treating older adults with ALL
35. Multiple isoforms of the Activin-like receptor baboon differentially regulate proliferation and conversion behaviors of neuroblasts and neuroepithelial cells in the Drosophila larval brain.
36. Chimeric Antigen Receptor-T Cells for Leukemias in Adults: Methods, Data and Challenges
37. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents
38. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
39. Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial
40. BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
41. Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
42. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
43. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
44. A Homeobox Transcription Factor Scarecrow (SCRO) Negatively Regulates Pdf Neuropeptide Expression through Binding an Identified cis-Acting Element in Drosophila melanogaster
45. Two-factor specification of apoptosis: TGF-β signaling acts cooperatively with ecdysone signaling to induce cell- and stage-specific apoptosis of larval neurons during metamorphosis in Drosophila melanogaster
46. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
47. Photoresponse of a strongly correlated material determined by scanning photocurrent microscopy
48. ALL-269 Safety and Pharmacokinetics of Calaspargase Pegol in Adults With Newly Diagnosed Philadelphia-Negative Acute Lymphoblastic Leukemia: A Phase 2/3 Study
49. Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia
50. Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.